Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

157.10 -1.15 (-0.73%)
Streaming Delayed Price Updated: 2:49 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Stock Market Pulls Back As Treasury Yields Jump; Google Dives On AI Flop: Weekly Review
Is this a normal, healthy pullback or the start of something more? 
Via Investor's Business Daily
Danaher, NextEra Energy, Paramount Global, AbbVie And This Mid-Cap ETF On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Shannon Saccocia of Boston Private named Danaher Corporation (NYSE: DHR) as 
Via Benzinga
AbbVie (ABBV) Q4 2022 Earnings Call Transcript
ABBV earnings call for the period ending December 31, 2022. 
Via The Motley Fool
AbbVie Beats On Q4 Earnings, Skyrizi Sales Grows 76%, Annual Guidance Lags Consensus
 
Via Benzinga
AbbVie Earnings Preview
 
Via Benzinga
2 Stocks Down More Than 6% to Buy Right Now
These companies outperformed the market last year. 
Via The Motley Fool
2 Steady Stocks to Buy in a Recession
Both companies are performing better than the broader market over the past year. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023
 
Via Benzinga
Do Humira Biosimilars Threaten AbbVie's Dividend?
Generic competition will eat at Humira's roughly $20 billion in annual sales. 
Via The Motley Fool
AbbVie Profit Outlook Widely Misses As The U.S. Humira Battle Kicks Off
The company's fourth quarter also came in mixed with lighter-than-expected sales. 
Via Investor's Business Daily
US Stocks On Recovery Course As Earnings Lend Support: Fed's Hawkish Stance May Unwind Rally In High-Value Names, Says Analyst
The see-sawing mood in the market continues as Fed’s data dependency creates volatility. The index futures point to a solidly higher opening on Thursday, signaling a reversal in the sentiment seen in... 
Via Benzinga
Thoughts For Thursday: Risk-off, Risk-on
The one foot forward, one foot backward action continues on Wall Street, though yesterday it was more like three or four steps backward. It seems Q1 earnings jitters are responsible. 
Via Talk Markets
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
These highly reliable healthcare stocks offer investors above-average dividend yields right now. 
Via The Motley Fool
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
On Tap: Earnings from Disney, Powell Speech as Market Digests Blockbuster Jobs Data
(Monday Market Open) Friday’s jobs report really put the Federal Reserve in a tough place. 
Via Benzinga
Five Best And Worst Performing Healthcare Stocks In January 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and... 
Via Talk Markets
3 Unstoppable Dividend Stocks to Buy in February
All three belong to the elite group of stocks known as Dividend Kings. 
Via The Motley Fool
If You Want Tons of Passive Income in the Future , Buy These 2 Stocks
Good cash flows come to those who pick intelligently and wait. 
Via The Motley Fool
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
The 3 Most Undervalued Penny Stocks to Buy in February 2023
Here are three penny stocks in emerging sectors that look to be undervalued relative to the consensus price target of analysts. 
Via InvestorPlace
2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade
These stocks are growing steadily and have a solid history of enriching shareholders. 
Via The Motley Fool
3 Ultra-Profitable Businesses to Invest in for the Long Haul
These companies all have profit margins of at least 20%. 
Via The Motley Fool
Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline
 
Via Benzinga
3 Juicy Dividend Stocks in Warren Buffett's Secret Portfolio to Buy in February
These stocks aren't in Berkshire Hathaway's SEC filings, but Buffett owns them. 
Via The Motley Fool
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
Amgen launched its biosimilar knockoff on Tuesday at a steep discount. 
Via Investor's Business Daily
These 3 Healthcare Stocks With Over 3% Dividend Yields Are Recommended By Benzinga's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%. 
Via Talk Markets
Down 14.5%, Is Pfizer Stock a Screaming Buy?
Pfizer's declining COVID-19 franchise and upcoming patent expirations have weighed heavily on its stock. 
Via The Motley Fool
S&P Global, AbbVie, And This Big 3 Automaker On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Karen Firestone of Aureus Asset Management said S&P Global Inc. (NYSE: SPGI) went through a lot during the past few years. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.